Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia
Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia
复制标题
DOI：
10.1177/0961203308100660
复制
发表时间：
2009-04-01
期刊：
影响因子：
2.6
通讯作者：
Khalil, N.
中科院分区：
文献类型：
--
作者：
Al Arfaj, A. S.;Khalil, N.
我们的目的是研究系统性红斑狼疮（SLE）患者的人口学、临床、实验室特征、治疗和预后。这项回顾性研究涵盖了27年（1980-2006），纳入了624例在利雅得哈立德国王大学医院就诊的SLE患者。女性566例，男性58例（9.8:1），平均年龄34.3岁（范围8-71岁），平均发病年龄25.3岁（范围0.08-67岁）。平均病程9.3年（0.3-30年）。最常见的疾病表现为血液学异常（82.7%）、关节炎（80.4%）和皮肤粘膜症状（64.3%）。其中，颧部皮疹占47.9%，盘状皮疹占17.6%，光敏性占30.6%，口腔溃疡占39.1%，浆液炎占27.4%，肾炎占47.9%，神经精神表现占27.6%。淋巴细胞减少症（40.3%）、抗ro（53.1%）、抗la（26.6%）、抗sm（41.6%）、抗心磷脂IgG（49.7%）、IgM（33.5%）抗体高发。99.7%的患者检测到抗核抗体，80.1%的患者检测到抗dna。低C3和低C4分别占45.4%和42.2%。治疗包括口服类固醇（96.2%）、静脉注射环磷酰胺（34.1%）和硫唑嘌呤（32.1%）以及其他药物。82.4%的患者获得长期缓解，2.6%的患者病情活跃，4.3%的患者发生肾功能衰竭，需要透析，6.7%的患者失去随访，4.0%的患者死亡。感染（48%）和活动性SLE（36%）是常见的死亡原因。5年和10年生存率分别为98%和97%。本研究表明，在我们的患者中，SLE表现出与其他阿拉伯国家和高加索地区SLE患者相似的特征。在我们的研究中，在一些中东和亚洲国家，与高加索人相比，抗ro抗体的患病率更高；这可能是由于遗传差异造成的种族间差异。我国患者5年生存率与西方国家相近，10年生存率优于大多数地方。狼疮（2009）18,465-473。
Our objective was to study the demographic, clinical, laboratory features, therapy, and outcome of systemic lupus erythematosus (SLE) patients. In this retrospective study, which covered a 27-year period (1980-2006), 624 SLE patients referring to King Khalid University hospital, Riyadh were included. There were 566 females and 58 males (9.8:1) with a mean age of 34.3 (range 8-71) years and mean age at disease onset of 25.3 years (range 0.08-67). The mean disease duration was 9.3 years (range 0.3-30). The most common disease manifestations were hematological abnormalities (82.7%), arthritis (80.4%), and mucocutaneous symptoms (64.3%). The prevalence of malar rash was 47.9%, discoid rash 17.6%, photosensitivity 30.6%, oral ulcers 39.1%, serositis 27.4%, nephritis 47.9%, and neuropsychiatric manifestations 27.6%. Lymphopenia (40.3%), anti-Ro (53.1%), anti-La (26.6%), anti-Sm (41.6%), anticardiolipin IgG (49.7%), and IgM (33.5%) antibodies were highly prevalent. Antinuclear antibodies were detected in 99.7% and anti-DNA in 80.1% patients. Low C3 and C4 were observed in 45.4% and 42.2%, respectively. Therapy included oral steroids (96.2%), IV cyclophosphamide (34.1%) and azathioprine (32.1%) along with other drugs. Long-term remission was achieved in 82.4%, disease was active in 2.6%, renal failure occurred in 4.3% requiring dialysis, 6.7% lost follow up and 4.0% patients died. Infections (48%) and active SLE (36%) were the common causes of death. The 5- and 10-year patient survival rate was 98% and 97%, respectively. This study suggests that, in our patients, SLE manifests with features similar to SLE patients from other Arab countries and Caucasia. In comparison to Caucasians, higher prevalence of anti-Ro antibodies is observed in our study, in some Middle-Eastern and Asian countries; this may likely be due to inter-ethnic variation owing to genetic differences. Our 5-year patient survival rate was similar to that of western countries, while 10-year survival rate was better than that of most places. Lupus (2009) 18, 465-473.